(Q42914090)

English

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

scientific article published on 7 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

phase III clinical trial

0 references

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

Gilda da Cunha Santos

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Jeremy A. Squire

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

object named as

Neesha Dhani

2

0 references

Ming-Sound Tsao

object named as

Ming Sound Tsao

10

0 references

Suzanne Kamel-Reid

object named as

Suzanne Kamel-Reid

6

0 references

author name string

Dongsheng Tu

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kayu Chin

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Olga Ludkovski

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Wendy Parulekar

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Malcolm J Moore

9

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

0 references

publication date

7 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

5599-5607

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

K-ras mutations in non-small-cell lung carcinoma: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25393

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25393

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42914090&oldid=1582927059"